Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-08-07
2007-08-07
Woitach, Joseph (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093100, C435S325000, C435S006120, C536S023500, C536S023520, C530S399000
Reexamination Certificate
active
10221975
ABSTRACT:
The present invention relates to the IL-12p40 subunit mutant gene which can produce IL-12(interleukin 12) of human and mouse origin with high activity, the expression vector including above mutant gene and the use of them to DNA vaccine adjuvant. Particularly, it relates to IL-12p40 mutant gene which inhibits the secretion of IL-12p40 but normally secretes active IL-12p70 by making mutation at Asn-222(human) or Asn-220(mouse) amino acid of IL-12p40, which acts as a competitive inhibitor of active form of IL-12, IL-12p70. Therefore, the IL-12p40 mutant gene of the present invention can be useful for DNA vaccination and gene therapy against various diseases, for example, AIDS, hepatitis C or hepatitis B, cancer, influenza, tuberculosis and malaria, which essentially require cellular immune responses for their therapy.
REFERENCES:
patent: 6517839 (2003-02-01), Modlin et al.
Deonarain (1998) Exp. Opin. Ther. Pat., 8(1): 53-69.
Gorecki (2001) Exp. Opin. Emerging Drugs, 6(2): 187-98.
Verma, et al. (1997) Nature, 389: 239-42.
Eck, et al. (1996) Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., McGraw-Hill, New York, NY., pp. 77-101.
J. Rudinger (1976) Peptide Hormones, Ed. JA. Parsons, University Park Press, Baltimore, MD., pp. 1-7.
Bowie, et al. (1990) Science, 247: 1306-10.
Ha, et al. (2002) Nature Biotech., 20: 381-86.
Accession. No. AAB62945 of GENEBANK, published Jul. 14, 1997, to Beyer, et al.
Song, et al. (2000) J. Virol., 74(6): 2920-25.
Masoumi, et al. (2003) Virus Research, 94: 113-120.
Gubler, et al. (1991) Proc. Natl. Acad. Sci., USA., 88: 4143-47.
Kim, et al. (1992) Molec. Cell. Biol., 12(8): 3636-43.
Ohlman, et al. (1999) RNA, 5(6): 764-78.
Rogozin, et al. (2001) Bioinformatics, 17(10): 890-900.
Saiz, et al. (1999) Arch. Virol., 144: 215-29.
Yap et al., J Immunol., Jul. 15, 2000; 165(2):628-31.
Stobie et al., Proc Natl Acad Sci USA, Jul. 18, 2000; 97(15):8427-32.
Gurunathan et al., J Immunol., Jul. 15, 2000; 165(2):915-24.
Lode et al., Proc Natl Acad Sci USA, Mar. 3, 1998; 95(5):2475-80.
Wang et al., Eur J Immunol., Jun. 1999; 29(6):2007-13.
Yoshimoto et al., J. Immunol., Jan. 15, 1998; 160(2):588-94.
Kieper et al., J Immunol., May 1, 2001; 166(9):5515-21.
Chang Jun
Ha Sang Jun
Lee Sung Hee
Song Man Ki
Sung Young Chul
Genexine Co. Ltd.
JHK Law
Kelly Robert M.
Woitach Joseph
LandOfFree
Genes of IL-12P40 subunit mutated for improving the activity... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Genes of IL-12P40 subunit mutated for improving the activity..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Genes of IL-12P40 subunit mutated for improving the activity... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3900007